Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321957 | 0.85 | PIK3CD (0.45) | PIK3CGPIK3CAPIK3CD | |
| SCHEMBL17893770 | 0.77 | ADAMTS5 (0.47) | — | |
| SCHEMBL17893801 | 0.77 | LMNA (0.47) | MAPT | |
| SCHEMBL10805715 | 0.76 | MEN1 (0.50) | SMN1; SMN2 | |
| SCHEMBL6353136 | 0.75 | CHRNB2 (0.74) | CHRNB2CHRNA4 | |
| SCHEMBL17893543 | 0.75 | P2RX3 (0.35) | — | |
| SCHEMBL17893620 | 0.75 | ADAMTS5 (0.48) | MAPT | |
| SCHEMBL171913 | 0.74 | ALDH1A1 (0.43) | PIK3CGCHRNB2CHRNA4PIK3CAPIK3CD | |
| SCHEMBL3544939 | 0.74 | LMNA (0.51) | — | |
| SCHEMBL7492716 | 0.74 | MAOB (0.44) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2426135-A1 | UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY | Shionogi&Co., Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | PIK3CG 16/4885CHRNB2 4863/4885CHRNA4 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.